Abstract
Molecular imaging is a useful tool for the in vivo validation of antibody therapeutics. It shows the accumulation properties of antibodies in tumors and organs that cannot be predicted by using in vitro assays. Two issues with characterizing antibodies using in vivo imaging are: (i) the fluorescent signal from the antibody is sensitive to its depth in the tissue, and (ii) there are large biological variabilities observed in in vivo imaging studies. Paired agent imaging measures the fluorescence of a test antibody and a control antibody in the same animal, allowing the fluorescence of the test antibody to be normalized to that of the control antibody. We used paired agent imaging to compare the in vivo imaging properties of two affinity-matured variants of the anti-EGFR antibody nimotuzumab (K4 and K5) to the parental antibody. To perform paired agent imaging, we labeled the test antibodies (K4 and K5) with IRDye800CW and the control antibody (nimotuzumab) labeled with IRDye680RD, and coinjected them into mice bearing EGFR-positive xenografts. Near-infrared fluorescent imaging was used to quantitate the relative amount of each antibody present in tumors and organs. Paired agent imaging allowed us to detect differences in in vivo fluorescence between K4, K5, and nimotuzumab, where K5 had the highest accumulation in the tumor, followed by K4 and nimotuzumab.